Update History
Syndrome: Factor V Leiden, Homozygous (also includes compound heterozygous FVL + prothrombin G20210A)
Gene/Gene Panel: F5
Updated By
Date
Status
Outcome-Interventions
Notes
Genboree Administrator Account
2018/11/01
Released
1.1.2
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 9CD
Pharmacological prophylaxis for men and non-pregnant women 6CD
Pharmacological prophylaxis for pregnant women 8CB
Internal system migration related to score text replacement from E to N
Liz Webber
2018/04/09
Released
1.1.1
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 9CD
Pharmacological prophylaxis for men and non-pregnant women 6CD
Pharmacological prophylaxis for pregnant women 8CB
Actionability Consensus Scorer
2018/03/19
Released
1.1.0
(Under Revision)
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CD
Pharmacological prophylaxis for men and non-pregnant women 6CD
Pharmacological prophylaxis for pregnant women 8CB
Kathleen Mittendorf
2018/01/11
Released
1.0.1
(Under Revision)
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 10CD
Pharmacological prophylaxis for men and non-pregnant women 7CD
Pharmacological prophylaxis for pregnant women 9CB
Elizabeth Clarke
2017/10/23
Released
1.0.0
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 10CD
Pharmacological prophylaxis for men and non-pregnant women 7CD
Pharmacological prophylaxis for pregnant women 9CB
¤ Powered by BCM's Genboree.